Mary Talley Bowden, a physician who endured a lengthy legal battle with the Texas Medical Board over her license to prescribe ivermectin, has finally been granted permission to sell the controversial drug. After facing scrutiny and opposition from medical authorities, Bowden can now offer ivermectin to her patients. This development marks a significant victory for Bowden, who has been fighting to provide this treatment option to her patients for years.
The decision to allow Bowden to sell ivermectin comes after a protracted legal dispute that garnered national attention. Bowden’s perseverance and dedication to advocating for the use of ivermectin in medical treatment have finally paid off. This victory not only benefits Bowden but also sets a precedent for other healthcare providers who may be facing similar challenges in prescribing certain medications.
In other news, the White House is reportedly planning to nominate a new leader for the Centers for Disease Control and Prevention (CDC) in the coming weeks. However, senators responsible for confirming the nominee have not been informed about the candidate. This lack of communication has raised concerns among lawmakers, who play a crucial role in the confirmation process for top government positions.
The appointment of a new CDC director is a critical decision that will have far-reaching implications for public health policy and response efforts. It is essential for the Senate to be kept informed and involved in the selection process to ensure transparency and accountability in government appointments. As the nation continues to navigate the ongoing challenges posed by the COVID-19 pandemic, strong leadership at the CDC is more important than ever.
For more updates and exclusive content on the politics and policy of health and medicine, subscribe to D.C. Diagnosis, STAT’s twice-weekly newsletter. Stay informed about the latest developments in healthcare and medical research by signing up to receive our newsletter directly in your inbox on Tuesdays and Thursdays.
